Expert Review of Anticancer Therapy

Papers
(The H4-Index of Expert Review of Anticancer Therapy is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
The RACE for children act at one year: progress in pediatric development of molecularly targeted oncology drugs80
Prognostic impact of renin-angiotensin system inhibitors in patients with ovarian cancer: a meta-analysis of real-world evidence72
Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review41
An evaluation of nivolumab plus gemcitabine and cisplatin in the treatment of advanced urothelial carcinoma40
Prostate and metastasis-directed focal therapy in prostate cancer: hype or hope?32
Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia28
Prevailing challenges in personalized treatment for metastatic renal cell carcinoma: a narrative review27
Clinical characteristics and outcomes among patients with subcutaneous panniculitis-like T-cell lymphoma27
PSMA-targeted radioligand therapy in prostate cancer: current status and future prospects26
Evaluating efficacy and safety of loncastuximab tesirine injection for the treatment of adult patients with relapsed or refractory large B-cell lymphoma24
Progress in the development of tissue-based biomarkers for urothelial cancer23
Current diagnostic and therapeutic options in de novo low-volume metastatic hormone-sensitive prostate cancer23
2021 ASCO genitourinary cancers symposium: a focus on renal cell carcinoma22
Current status and novel insights into the role of metastasectomy in the era of immunotherapy21
Efficacy and toxicity of drugs targeting KRAS G12C mutation in non-small cell lung cancer: a meta-analysis21
Neoadjuvant endocrine therapy in postmenopausal women with HR+/HER2- breast cancer20
Progress in histology specific treatments in soft tissue sarcoma20
The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan20
Current management of familial adenomatous polyposis19
Avapritinib in unresectable or metastatic gastrointestinal stromal tumor with PDGFRA exon 18 mutation: safety and efficacy19
Primary effusion lymphoma: therapeutic strategies targeting viral and cellular mechanisms19
0.054971933364868